Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

Cell Reports

Volumn 22, Issue 7, 2018, Pages 1798-1809

  Kwon, Young D ^a   Chuang, Gwo Yu ^a   Zhang, Baoshan ^a   Bailer, Robert T ^a   Doria Rose, Nicole A ^a   Gindin, Tatyana S ^b   Lin, Bob ^a   Louder, Mark K ^a   McKee, Krisha ^a   O'Dell, Sijy ^a   Pegu, Amarendra ^a   Schmidt, Stephen D ^a   Asokan, Mangaiarkarasi ^a   Chen, Xuejun ^a   Choe, Misook ^a   Georgiev, Ivelin S ^a   Jin, Vivian ^a   Pancera, Marie ^a   Rawi, Reda ^a   Wang, Keyun ^a   Chaudhuri, Rajoshi ^a   Kueltzo, Lisa A ^a   Manceva, Slobodanka D ^a   Todd, John Paul ^a   Scorpio, Diana G ^a   Kim, Mikyung ^c   Reinherz, Ellis L ^c   Wagh, Kshitij ^d   Korber, Bette M ^d   Connors, Mark ^a   Shapiro, Lawrence ^e   Mascola, John R ^a   Kwong, Peter D ^a,e   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Department of Medicine   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e NONE   (United States)

Author keywords

10E8; antibody improvement; broadly neutralizing antibody; HIV 1; membrane proximal external region; MPER; surface matrix screening

Indexed keywords

ARGININE; HUMAN IMMUNODEFICIENCY VIRUS 1 NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10E8; NEUTRALIZING ANTIBODY; PHENYLALANINE; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; POLYSACCHARIDE; PROTEIN BINDING;

AMINO ACID MUTATION; AMINO ACID SUBSTITUTION; ANTIGEN ANTIBODY REACTION; ARTICLE; BIOLAYER INTERFEROMETRY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; INTERFEROMETRY; MEMBRANE BINDING; MEMBRANE PROXIMAL EXTERNAL REGION; MUTATION; NONHUMAN; POLYREACTIVITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; SCREENING; SURFACE MATRIX SCREENING; SURFACE PLASMON RESONANCE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; CELL MEMBRANE; HALF LIFE TIME; HUMAN; IMMUNOLOGY; METABOLISM; SERODIAGNOSIS;

ANTIBODIES, NEUTRALIZING; CELL MEMBRANE; HALF-LIFE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; NEUTRALIZATION TESTS; POLYSACCHARIDES; PROTEIN BINDING;

EID: 85042038561     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.01.023     Document Type: Article

References (51)

1. Ayyar, B.V., Arora, S., O'Kennedy, R., Coming-of-age of antibodies in cancer therapeutics. Trends Pharmacol. Sci. 37 (2016), 1009–1028.
2. Bar, K.J., Sneller, M.C., Harrison, L.J., Justement, J.S., Overton, E.T., Petrone, M.E., Salantes, D.B., Seamon, C.A., Scheinfeld, B., Kwan, R.W., et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375 (2016), 2037–2050.
3. Cardoso, R.M., Zwick, M.B., Stanfield, R.L., Kunert, R., Binley, J.M., Katinger, H., Burton, D.R., Wilson, I.A., Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 (2005), 163–173.
4. Caskey, M., Klein, F., Lorenzi, J.C., Seaman, M.S., West, A.P. Jr., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J.F., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
5. Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E.F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T.Y., et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23 (2017), 185–191.
6. Chames, P., Van Regenmortel, M., Weiss, E., Baty, D., Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157 (2009), 220–233.
7. Chuang, G.Y., Boyington, J.C., Joyce, M.G., Zhu, J., Nabel, G.J., Kwong, P.D., Georgiev, I., Computational prediction of N-linked glycosylation incorporating structural properties and patterns. Bioinformatics 28 (2012), 2249–2255.
8. Diskin, R., Scheid, J.F., Marcovecchio, P.M., West, A.P. Jr., Klein, F., Gao, H., Gnanapragasam, P.N., Abadir, A., Seaman, M.S., Nussenzweig, M.C., Bjorkman, P.J., Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334 (2011), 1289–1293.
9. Gorman, J., Soto, C., Yang, M.M., Davenport, T.M., Guttman, M., Bailer, R.T., Chambers, M., Chuang, G.Y., DeKosky, B.J., Doria-Rose, N.A., et al., NISC Comparative Sequencing Program. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 23 (2016), 81–90.
10. Hebert, D.N., Lamriben, L., Powers, E.T., Kelly, J.W., The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis. Nat. Chem. Biol. 10 (2014), 902–910.
11. Huang, J., Ofek, G., Laub, L., Louder, M.K., Doria-Rose, N.A., Longo, N.S., Imamichi, H., Bailer, R.T., Chakrabarti, B., Sharma, S.K., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491 (2012), 406–412.
12. Huang, J., Kang, B.H., Ishida, E., Zhou, T., Griesman, T., Sheng, Z., Wu, F., Doria-Rose, N.A., Zhang, B., McKee, K., et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45 (2016), 1108–1121.
13. Huang, Y., Yu, J., Lanzi, A., Yao, X., Andrews, C.D., Tsai, L., Gajjar, M.R., Sun, M., Seaman, M.S., Padte, N.N., Ho, D.D., Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165 (2016), 1621–1631.
14. Hubbard, S.J., Thornton, J.M., NACCESS computer program. 1993, Department of Biochemistry and Molecular Biology, University College London.
15. Hwang, W.Y., Foote, J., Immunogenicity of engineered antibodies. Methods 36 (2005), 3–10.
16. Irimia, A., Sarkar, A., Stanfield, R.L., Wilson, I.A., Crystallographic identification of lipid as an integral component of the epitope of HIV broadly neutralizing antibody 4E10. Immunity 44 (2016), 21–31.
17. Irimia, A., Serra, A.M., Sarkar, A., Jacak, R., Kalyuzhniy, O., Sok, D., Saye-Francisco, K.L., Schiffner, T., Tingle, R., Kubitz, M., et al. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog., 13, 2017, e1006212.
18. Klein, F., Halper-Stromberg, A., Horwitz, J.A., Gruell, H., Scheid, J.F., Bournazos, S., Mouquet, H., Spatz, L.A., Diskin, R., Abadir, A., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492 (2012), 118–122.
19. Kong, R., Louder, M.K., Wagh, K., Bailer, R.T., deCamp, A., Greene, K., Gao, H., Taft, J.D., Gazumyan, A., Liu, C., et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 89 (2015), 2659–2671.
20. Kwon, Y.D., Georgiev, I.S., Ofek, G., Zhang, B., Asokan, M., Bailer, R.T., Bao, A., Caruso, W., Chen, X., Choe, M., et al. Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design. J. Virol. 90 (2016), 5899–5914.
21. Lee, J.H., Ozorowski, G., Ward, A.B., Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351 (2016), 1043–1048.
22. Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K.M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 (2005), 10108–10125.
23. McLellan, J.S., Pancera, M., Carrico, C., Gorman, J., Julien, J.P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480 (2011), 336–343.
24. Ofek, G., Tang, M., Sambor, A., Katinger, H., Mascola, J.R., Wyatt, R., Kwong, P.D., Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 (2004), 10724–10737.
25. Ofek, G., McKee, K., Yang, Y., Yang, Z.Y., Skinner, J., Guenaga, F.J., Wyatt, R., Zwick, M.B., Nabel, G.J., Mascola, J.R., Kwong, P.D., Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J. Virol. 84 (2010), 2955–2962.
26. Pancera, M., Zhu, J., O'Dell, S., Yang, Y., Zhang, B., Changela, A., McLellan, J.S., Wu, X., Zhou, T., Burton, D.R., et al. Arginine-scanning of PG16 paratope defines quaternary epitope. AIDS Res. Hum. Retroviruses 29 (2013), A59–A60.
27. Ramilo, O., Lagos, R., Sáez-Llorens, X., Suzich, J., Wang, C.K., Jensen, K.M., Harris, B.S., Losonsky, G.A., Griffin, M.P., Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr. Infect. Dis. J. 33 (2014), 703–709.
28. Robison, A.D., Sun, S., Poyton, M.F., Johnson, G.A., Pellois, J.P., Jungwirth, P., Vazdar, M., Cremer, P.S., Polyarginine interacts more strongly and cooperatively than polylysine with phospholipid bilayers. J. Phys. Chem. B 120 (2016), 9287–9296.
29. Roopenian, D.C., Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (2007), 715–725.
30. Rudicell, R.S., Kwon, Y.D., Ko, S.Y., Pegu, A., Louder, M.K., Georgiev, I.S., Wu, X., Zhu, J., Boyington, J.C., Chen, X., et al., NISC Comparative Sequencing Program. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88 (2014), 12669–12682.
31. Rujas, E., Caaveiro, J.M., Insausti, S., García-Porras, M., Tsumoto, K., Nieva, J.L., Peripheral membrane interactions boost the engagement by an anti-HIV-1 broadly neutralizing antibody. J. Biol. Chem. 292 (2017), 5571–5583.
32. Sarzotti-Kelsoe, M., Bailer, R.T., Turk, E., Lin, C.L., Bilska, M., Greene, K.M., Gao, H., Todd, C.A., Ozaki, D.A., Seaman, M.S., et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409 (2014), 131–146.
33. Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333 (2011), 1633–1637.
34. Scheid, J.F., Horwitz, J.A., Bar-On, Y., Kreider, E.F., Lu, C.L., Lorenzi, J.C., Feldmann, A., Braunschweig, M., Nogueira, L., Oliveira, T., et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535 (2016), 556–560.
35. Schoofs, T., Klein, F., Braunschweig, M., Kreider, E.F., Feldmann, A., Nogueira, L., Oliveira, T., Lorenzi, J.C., Parrish, E.H., Learn, G.H., et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352 (2016), 997–1001.
36. Seaman, M.S., Janes, H., Hawkins, N., Grandpre, L.E., Devoy, C., Giri, A., Coffey, R.T., Harris, L., Wood, B., Daniels, M.G., et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84 (2010), 1439–1452.
37. Song, L., Sun, Z.Y., Coleman, K.E., Zwick, M.B., Gach, J.S., Wang, J.H., Reinherz, E.L., Wagner, G., Kim, M., Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc. Natl. Acad. Sci. USA 106 (2009), 9057–9062.
38. Song, R., Oren, D.A., Franco, D., Seaman, M.S., Ho, D.D., Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat. Biotechnol. 31 (2013), 1047–1052.
39. Soto, C., Ofek, G., Joyce, M.G., Zhang, B., McKee, K., Longo, N.S., Yang, Y., Huang, J., Parks, R., Eudailey, J., et al., NISC Comparative Sequencing Program. Developmental pathway of the MPER-directed HIV-1-neutralizing antibody 10E8. PLoS ONE, 11, 2016, e0157409.
40. Stewart-Jones, G.B., Soto, C., Lemmin, T., Chuang, G.Y., Druz, A., Kong, R., Thomas, P.V., Wagh, K., Zhou, T., Behrens, A.J., et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165 (2016), 813–826.
41. Sun, Z.Y., Oh, K.J., Kim, M., Yu, J., Brusic, V., Song, L., Qiao, Z., Wang, J.H., Wagner, G., Reinherz, E.L., HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28 (2008), 52–63.
42. Trevino, S.R., Scholtz, J.M., Pace, C.N., Amino acid contribution to protein solubility: Asp, Glu, and Ser contribute more favorably than the other hydrophilic amino acids in RNase Sa. J. Mol. Biol. 366 (2007), 449–460.
43. Wagh, K., Bhattacharya, T., Williamson, C., Robles, A., Bayne, M., Garrity, J., Rist, M., Rademeyer, C., Yoon, H., Lapedes, A., et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog., 12, 2016, e1005520.
44. Wibmer, C.K., Gorman, J., Ozorowski, G., Bhiman, J.N., Sheward, D.J., Elliott, D.H., Rouelle, J., Smira, A., Joyce, M.G., Ndabambi, N., et al. Structure and recognition of a novel HIV-1 gp120-gp41 interface antibody that caused MPER exposure through viral escape. PLoS Pathog., 13, 2017, e1006074.
45. Williams, L.T.D., Ofek, G., Schatzle, S., McDaniel, J.R., Lu, X., Nicely, N.I., Wu, L., Lougheed, C., Bradley, T., Louder, M., et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci. Immunol., 2, 2017, eaal2200.
46. Wu, H., Pfarr, D.S., Johnson, S., Brewah, Y.A., Woods, R.M., Patel, N.K., White, W.I., Young, J.F., Kiener, P.A., Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368 (2007), 652–665.
47. Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
48. Xu, L., Pegu, A., Rao, E., Doria-Rose, N., Beninga, J., McKee, K., Lord, D.M., Wei, R.R., Deng, G., Louder, M., et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358 (2017), 85–90.
49. Young, L., Jernigan, R.L., Covell, D.G., A role for surface hydrophobicity in protein-protein recognition. Protein Sci. 3 (1994), 717–729.
50. Zalevsky, J., Chamberlain, A.K., Horton, H.M., Karki, S., Leung, I.W., Sproule, T.J., Lazar, G.A., Roopenian, D.C., Desjarlais, J.R., Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28 (2010), 157–159.
51. Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I.S., Altae-Tran, H.R., Chuang, G.Y., Joyce, M.G., et al., NISC Comparative Sequencing Program. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39 (2013), 245–258.